This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930
by Zacks Equity Research
BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.
Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study
by Zacks Equity Research
The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.
Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.
Horizon (HZNP) Gets Positive CHMP Opinion for Uplizna in NMOSD
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Horizon's (HZNP) Uplizna for treating adult patients with neuromyelitis optica spectrum disorder.
VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 71.43% and 130.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: vTv Therapeutics (VTVT) Q3 Earnings Expected to Decline
by Zacks Equity Research
VTv Therapeutics (VTVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.
Company News for Sep 27, 2021
by Zacks Equity Research
Companies in the news are: MDP, VTVT, MRIN and COST
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.
Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround
by Zacks Equity Research
vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
VTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 85.71% and -99.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
VTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -50.00% and 23.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Company News for Apr 14, 2021
by Zacks Equity Research
Companies in the news are: MFNC, NVCR, RIGL, VTVT
vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.
vTv Therapeutics' (VTVT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in vTv Therapeutics (VTVT).
Has vTv Therapeutics (VTVT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VTVT) Outperforming Other Medical Stocks This Year?
vTv Therapeutics Inc. (VTVT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in vTv Therapeutics Inc. (VTVT).
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
VTv Therapeutics (VTVT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 9.09% and -99.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
by Kinjel Shah
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
by Zacks Equity Research
Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
Get Over Bargain Hunting: Tap 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 60.00% and 63.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
VTv Therapeutics (VTVT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
VTv Therapeutics (VTVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
vTv Therapeutics (VTVT) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.